POST Online Media Lite Edition



 

EU concludes talks with Sanofi to secure 300 mln doses of coronavirus vaccine

Christian Fernsby |
The European Commission said on Friday that it has concluded exploratory talks with French pharmaceutical company Sanofi aiming for a deal that could secure 300 million doses of the company's COVID-19 vaccine for Europeans next year.

Topics: SANOFI   

It is part of a broader European Union (EU) campaign seeking to reach purchase agreements with major COVID-19 vaccine manufacturers.

Sanofi's vaccine candidate is planning to seek marketing authorization from the European Medicines Agency in June 2021 following Phase III clinical trials.

The commission said in a statement that it would have a contractual framework in place for the purchase of 300 million doses on behalf of all EU member states once Sanofi's vaccine has proven to be safe and effective against COVID-19.

According to the EU strategy for COVID-19 vaccines, the commission would finance part of the upfront costs faced by vaccine producers in the form of Advance Purchase Agreements. Funding provided would be considered as a down payment on the vaccines to be purchased by the EU member states.


What to read next

Sanofi and Boehringer will swap businesses
Sanofi sues Novo Nordisk over diabetes drugs in U.S.
Sanofi Pasteur agrees to refund $27.8 million to Philippines